Get the Daily Brief
Latest Biotech News
Trop-2 ADC failure reshapes first-line NSCLC strategy
Gilead and Merck shut down the phase 3 Evoke-03 trial after interim analyses indicated Trodelvy plus Keytruda was unlikely to meet the progression-free survival endpoint in first-line PD-L1-high...
HIV innovation moves toward the first weekly oral regimen
Merck and Gilead reported positive phase 3 results for a weekly oral HIV regimen combining Merck’s islatravir and Gilead’s lenacapavir. In both Islend-1 and Islend-2, the study met its primary...
New blood-disorder bet: Incyte snaps up Vega for Phase III VWD antibody
Incyte agreed to acquire Vega Therapeutics for up to $2 billion, adding VGA039, a Phase III monoclonal antibody candidate in von Willebrand disease. The deal is designed to bolster Incyte’s...
Oncology diagnostics scale-up: CRUK and Guardant expand ctDNA access
Cancer Research UK partnered with the Royal Marsden NHS Foundation Trust and Guardant Health to make ctDNA testing freely available to hundreds of advanced solid-tumor patients across the ECMC...
Product innovation: Personalis receives CE-IVD for blood collection kits
Personalis won CE-IVD marking for its EDTA and cfDNA blood collection kits in the EU, clearing the way to market the specimen products that support its ultrasensitive NeXT Personal assay. The kits...
Clinical prevention push: Dual Lassa-rabies vaccine shows early immunogenicity and safety
Researchers from the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim phase 1 data for a dual Lassa fever–rabies vaccine candidate...
IPO and public-market access: Parabilis eyes potentially record-breaking financing
Parabilis Medicines moved to upsize its IPO plans, signaling intent to pursue a potentially record-setting $637 million fundraising. The company’s plans arrive amid sustained demand in biotech...
Reverse merger: Treeline plans Nasdaq debut with Standard BioTools
Treeline Biosciences announced plans to go public through a reverse merger with Standard BioTools, creating a combined company expected to trade on the Nasdaq under the Treeline name. The deal...
Emerging platform and funding: City Therapeutics drives RNAi pipeline with Series B
City Therapeutics closed a $99.5 million Series B financing to advance its RNA interference pipeline and fund expansion of its next-generation RNAi engineering platform. The company said it will...
Large-cap oncology M&A accelerates lung cancer franchises
GSK moved to bolster its near-commercial lung cancer pipeline, agreeing to buy Nuvalent for about $10.6 billion in cash. The acquisition adds two programs under FDA review—zidesamtinib (ROS1) and...
First weekly HIV pill moves closer after phase 3 wins
Merck and Gilead reported positive phase 3 results for a weekly oral HIV regimen combining islatravir and lenacapavir, with both studies meeting their primary efficacy endpoints. The companies...
Biopharma record-setting IPO backs next oncology wave
Parabilis pursued a potentially record-setting Nasdaq debut, launching an IPO valued at about $670 million and earmarking proceeds to fund a cancer drug program. The company’s move comes amid...
Incyte pushes deeper into hematology with Vega’s Phase 3 VWD asset
Incyte agreed to acquire Vega Therapeutics for up to $2 billion, aiming to extend its hematology growth engine with a Phase 3 von Willebrand disease (VWD) candidate. Vega’s VGA039 is positioned as...
J&J enters degrader antibody conjugates with Firefly Bio
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, targeting a new therapeutic modality in degraders delivered via antibody conjugates. The acquisition is designed to broaden...
Gilead’s Trodelvy hits a first-line NSCLC wall
Gilead and Merck said they will stop a Phase 3 trial of Trodelvy (sacituzumab govitecan) plus Keytruda in first-line PD-L1-high non-small cell lung cancer after an external data monitoring...
Regulatory momentum in AI-enabled diagnostics and liquid biopsy
Cancer Research UK, Royal Marsden and Guardant Health partnered to expand access to ctDNA testing across the UK’s Experimental Cancer Medicine Centre (ECMC) network. CRUK said it aims to make...
Modernizing clinical trial diagnostics infrastructure via platform acquisitions
10x Genomics expanded its proteomics capabilities through the acquisition of Proteintech Genomics, aiming to integrate transcriptomic and proteomic measurements across its single-cell and spatial...
Treeline’s move to public markets via reverse merger
Treeline Biosciences outlined plans to go public through a reverse merger with Standard BioTools, with the combined company expected to trade on Nasdaq under the Treeline Biosciences name. The...
AI transforms antibody design with multi-objective learning
Researchers reported progress in multi-objective antibody design using machine learning, aiming to optimize multiple functional attributes simultaneously rather than sequentially tuning single...
GSK expands lung cancer franchise via Nuvalent acquisition
GSK agreed to acquire Nuvalent for $10.6 billion in cash, positioning the deal to add two near-commercial non-small cell lung cancer (NSCLC) programs to its pipeline. The acquisition brings...